泰格醫藥(300347.SZ):H股穩價期結束 悉數行使超配權
格隆匯8月31日丨泰格醫藥(300347.SZ)宣佈,公司境外上市外資股(H股)全球發售的穩定價格期於2020年8月30日(即遞交香港公開發售境外上市外資股(H股)認購申請截止日期後的第30日)結束。
穩定價格經辦人或代其行動的人士於穩定價格期內採取的穩定價格行動包括:
1、在國際發售中超額配售共計1605.97萬股境外上市外資股(H股),相當於全球發售初步可供認購的發售股份總數(於行使任何超額配售權前)約15.00%;
2、聯席全球協調人(代表國際承銷商)於2020年8月29日按每股境外上市外資股(H股)發售價格就合計1605.97萬股境外上市外資股(H股)(約為任何超額配售權獲行使之前全球發售初步可供認購的發售股份總數的15%)悉數行使超額配售權,以補足國際發售的超額配發。
行使超額配售權之後,公司將繼續符合香港聯交所授出的關於豁免嚴格遵守《香港聯合交易所有限公司證券上市規則》第8.08(1)(b)條的豁免函所規定條件中的最低百分比。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.